NO986100L - Androgene reseptormodulerende forbindelser og fremgangsmÕter - Google Patents

Androgene reseptormodulerende forbindelser og fremgangsmÕter

Info

Publication number
NO986100L
NO986100L NO986100A NO986100A NO986100L NO 986100 L NO986100 L NO 986100L NO 986100 A NO986100 A NO 986100A NO 986100 A NO986100 A NO 986100A NO 986100 L NO986100 L NO 986100L
Authority
NO
Norway
Prior art keywords
compounds
androgen receptor
methods
disclosed
modulating compounds
Prior art date
Application number
NO986100A
Other languages
English (en)
Other versions
NO986100D0 (no
NO311645B1 (no
Inventor
James P Edwards
Robert Huguchi
Todd Jones
Original Assignee
Ligand Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceutical Inc filed Critical Ligand Pharmaceutical Inc
Publication of NO986100D0 publication Critical patent/NO986100D0/no
Publication of NO986100L publication Critical patent/NO986100L/no
Publication of NO311645B1 publication Critical patent/NO311645B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
NO19986100A 1996-06-27 1998-12-23 Androgene reseptormodulerende forbindelser NO311645B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2199796P 1996-06-27 1996-06-27
PCT/US1997/011222 WO1997049709A1 (en) 1996-06-27 1997-06-26 Androgen receptor modulator compounds and methods

Publications (3)

Publication Number Publication Date
NO986100D0 NO986100D0 (no) 1998-12-23
NO986100L true NO986100L (no) 1998-12-23
NO311645B1 NO311645B1 (no) 2001-12-27

Family

ID=21807289

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19986100A NO311645B1 (no) 1996-06-27 1998-12-23 Androgene reseptormodulerende forbindelser

Country Status (12)

Country Link
EP (1) EP0918774B9 (no)
JP (1) JP2000513362A (no)
AT (1) ATE209207T1 (no)
AU (1) AU728178B2 (no)
BR (1) BR9710988A (no)
DE (1) DE69709752T2 (no)
DK (1) DK0918774T3 (no)
ES (1) ES2168650T3 (no)
NO (1) NO311645B1 (no)
PT (1) PT918774E (no)
RU (1) RU2214412C2 (no)
WO (1) WO1997049709A1 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6253061B1 (en) 1997-09-19 2001-06-26 Richard J. Helferich Systems and methods for delivering information to a transmitting and receiving device
US6826407B1 (en) 1999-03-29 2004-11-30 Richard J. Helferich System and method for integrating audio and visual messaging
US7003304B1 (en) 1997-09-19 2006-02-21 Thompson Investment Group, Llc Paging transceivers and methods for selectively retrieving messages
US6636733B1 (en) 1997-09-19 2003-10-21 Thompson Trust Wireless messaging method
US6983138B1 (en) 1997-12-12 2006-01-03 Richard J. Helferich User interface for message access
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
EP1216221A2 (en) 1999-09-14 2002-06-26 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US20030175817A1 (en) * 2000-02-10 2003-09-18 Kyoji Ikeda Method of screening for antiandrogen agent
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
AU2002215609A1 (en) * 2000-06-28 2002-01-08 Bristol-Myers Squibb Company Fused cyclic compounds as modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US7018993B2 (en) 2000-06-30 2006-03-28 Chugai Seiyaku Kabushiki Kaisha Antiandrogenic agent
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
ES2260244T3 (es) * 2000-09-19 2006-11-01 Bristol-Myers Squibb Company Compuesto de succinamida heterociclicos condensados y analogos de los mismos, moduladores de la funcion del receptor nuclear de hormona.
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
WO2003034987A2 (en) * 2001-10-19 2003-05-01 Merck & Co., Inc. Androgen receptor modulators and methods of use thereof
HUP0500096A3 (en) 2001-12-19 2012-08-28 Bristol Myers Squibb Co Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function, process for producing them and pharmaceutical compositions containing them
US20050101657A1 (en) * 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
US7705182B2 (en) 2002-02-28 2010-04-27 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
JP4746840B2 (ja) * 2002-04-26 2011-08-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド アンドロゲン受容体モジュレーターとしての２−（キノロニル）−縮合複素環化合物
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
MXPA05007605A (es) 2003-01-17 2005-09-30 Warner Lambert Co Antagonista del receptor de androgenos.
AU2004266160A1 (en) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1991223B1 (en) * 2006-02-10 2010-07-14 Janssen Pharmaceutica, N.V. Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
RU2381229C2 (ru) * 2007-10-17 2010-02-10 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 11b-(ГEТ)АРИЛ-2,3,6,11b-ТЕТРАГИДРООКСАЗОЛО[2',3':2,1]ПИРРОЛО[3,4-b]ХИНОЛИН-5,11-ДИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
AU2009215843B2 (en) 2008-02-22 2011-09-08 Ellipses Pharma Ltd Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
SG175377A1 (en) * 2009-04-30 2011-12-29 Nissan Chemical Ind Ltd Novel crystal forms of tricyclic benzopyran compound and processes for producing same
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
CA2824521C (en) 2011-01-20 2016-06-28 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and related methods
EP4035664A3 (en) 2014-03-28 2022-11-30 Duke University Treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RU2769527C2 (ru) 2016-06-22 2022-04-01 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用
CN106565723B (zh) * 2016-11-04 2019-08-27 江苏师范大学 一种呋喃并吡啶、苯并吡啶类衍生化合物的制备方法
DK3565542T3 (da) 2017-01-05 2024-07-01 Radius Pharmaceuticals Inc Polymorphic forms of rad1901-2hcl
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
CN116969959B (zh) * 2023-08-03 2025-10-31 浙江大学 取代四氢喹啉类衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
US5677336A (en) * 1993-10-21 1997-10-14 Ligand Pharmaceuticals Incorporated Non-steroid androgen receptor antagonist compounds and methods
CZ176197A3 (cs) * 1994-12-22 1998-09-16 Ligand Pharmaceuticals Incorporated Modulátory steroidových receptorů a způsoby jejich přípravy a použití

Also Published As

Publication number Publication date
NO986100D0 (no) 1998-12-23
EP0918774A1 (en) 1999-06-02
DE69709752T2 (de) 2002-07-18
WO1997049709A1 (en) 1997-12-31
DE69709752D1 (de) 2002-02-21
EP0918774B9 (en) 2002-04-10
BR9710988A (pt) 2002-01-15
ATE209207T1 (de) 2001-12-15
NO311645B1 (no) 2001-12-27
PT918774E (pt) 2002-05-31
DK0918774T3 (da) 2002-05-21
ES2168650T3 (es) 2002-06-16
EP0918774B1 (en) 2001-11-21
RU2214412C2 (ru) 2003-10-20
JP2000513362A (ja) 2000-10-10
AU3508497A (en) 1998-01-14
AU728178B2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
NO986100D0 (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
DE69531403D1 (de) Allosterische modulatoren des nmda-rezeptors
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
DK0873295T3 (da) Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
YU7797A (sh) Kombinovana terapija za osteoporozu
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
AP9801269A0 (en) Prostaglandin agonists.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DK0874625T3 (da) Indanderivater til antipsykotiske præparater
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
AU7525398A (en) Inhibitors for urokinase receptor
CA2259031A1 (en) Androgen receptor modulator compounds and methods